

Nutrients and Botanicals in the Treatment of Diabetes in Veterinary Practice

Susan Wynn, DVM, CVA

Abstract

Diabetes mellitus can be frustrating to treat in veterinary practice, but botanical and nutritional supplements may offer assistance in stabilizing difficult patients. While dogs are typically subject to type 1 diabetes, cats develop type 2 diabetes as much as 70 percent of the time. Whereas treatment adjuncts to insulin may address carbohydrate metabolism from glucose absorption to insulin receptor function, success may depend on the type of diabetes present in the patient.

(*Altern Med Rev* 2001;6 (Suppl):S17-S23)

Regulators of Glucose Absorption

Dietary therapy has been and will remain a mainstay of diabetes treatment. Dietary fiber has been shown to reduce glucose absorption from the gut, increasing glycemic control. Insoluble fiber (in the form of 12-percent cellulose incorporated into the diet) was shown to reduce glucose absorption in cats¹ and dogs² in randomized, crossover trials. Another study in dogs with insulin-dependent diabetes compared fiber content of several diets and their effect on insulin dosage and blood glucose concentrations. Dogs were randomly assigned either a low-fiber diet, a high insoluble-fiber diet, or a high soluble-fiber diet. While there was no significant difference in insulin requirements among the three groups, the insoluble-fiber diet resulted in significantly lower blood glucose concentrations, compared to the low-fiber and soluble-fiber diets.³

On the other hand, another study found soluble fibers, such as guar gum, to offer possible protection for diabetes and hyperlipidemia. Healthy beagles were fed a diet of seven-percent fiber: either guar gum, inulin, or sugar beet fiber. While neither sugar beet fiber nor inulin had a metabolic effect on the dogs, guar gum resulted in decreased postprandial insulin and fasting cholesterol. The researchers concluded that “Guar gum would be a suitable ingredient for dietary therapy of chronic diseases such as diabetes mellitus or hyperlipidemia in the dog.”⁴ Some of these same researchers found both sugar beet fiber and fructo-oligosaccharides (fermentable fibers) fed to healthy beagles resulted in a significant decrease in triglycerides and postprandial glucose.⁵ Sources of soluble fiber are legumes (one of the best), whole grains, vegetables, and fruits – most of which also contain some insoluble fiber. Insoluble fiber supplementation may be supplied via vegetables and whole grains.

In humans it appears insulin resistance may develop (in part) from a high carbohydrate diet,⁶ a theory particularly interesting considering the typical dry diet fed veterinary patients. Cats (obligate carnivores) and dogs (facultative carnivores) may, in fact, have innate insulin resistance mechanisms, making them less tolerant of the highly digestible carbohydrate diets

Susan Wynn, DVM, CVA – is a two-time grant review panelist of the National Institutes of Health. She is also the author of *Emerging Therapies: Herbal and Nutritional Medicine for Small Animals*. Correspondence address: 1080 North Cobb Parkway, Marietta, GA 30062

recommended in principle for humans, and provided by typical dry commercial diets. It is well to remember that cats have no requirement for carbohydrates whatsoever; therefore, insulin resistance may have developed in this species as a mechanism for coping with exogenous glucose shortages. It is possible the progression of diabetes is hastened by feeding diabetic cats and dogs a high-carbohydrate dry diet.

While the role of obesity in the development of diabetes is well recognized, the connection between veterinary weight loss diets and obese diabetic pets has not received sufficient attention. The development of insulin resistance is seen particularly in cats, possibly due to a lifetime of dry, high-carbohydrate commercial foods. On the other hand, the overweight (and normal weight) diabetic cat is usually fed a low-fat, free choice, high-carbohydrate weight loss diet. Since many overweight cats return to a non-diabetic state when their weight is normalized, dietary management of these cats is of particular concern. Managing overweight cats is often complicated, as hepatic lipidosis occurs easily and is potentially fatal. A discussion of weight management in these cats is beyond the scope of this paper, but should be undertaken with care.

In any event, the time has come to re-evaluate dietary recommendations for the overweight diabetic veterinary patient. To this end, some are feeding a high-quality maintenance diet – prescription or homemade – with quality meat protein and lower digestible carbohydrate levels, adding insoluble fibers (vegetables, wheat bran) to take advantage of fiber's effect on glycemic control. This is particularly important when a pet is a so-called "picky" eater or has nutritional needs not covered by a commercial, high-fiber, weight-loss diet (e.g., food allergies, renal failure, etc.). Recently, one pet food manufacturer introduced a low-carbohydrate diet specifically for managing diabetes in cats.

Regulators of Insulin Availability or Release

Botanicals

Gymnema sylvestre is an herb that has been used in Ayurvedic medicine for 2,000 years in treating diabetes. Recent clinical and experimental studies suggest this use is warranted. Numerous case series reports indicate that *Gymnema* improves glucose tolerance and clinical status in human diabetics. *Gymnema* extract was shown to increase insulin secretion in pancreatic beta-cell lines by increasing membrane permeability.⁷ In streptozocin-treated rats, administration of *Gymnema* extract was observed to increase serum insulin levels as well as the absolute number of pancreatic islet cells. The same group showed *Gymnema* improved glucose uptake in target tissues.^{8,9} Clinical use suggests *Gymnema* must be administered for two to three months for maximum effect. Although the herb is available alone, it is more often used in combination with other herbs traditionally used in the treatment of diabetes, including *Momordica charantia* (bitter melon), fenugreek, and ginseng.

The herb *Momordica charantia* has a long history of use in China, India, and Africa for the treatment of human diabetes. The hypoglycemic constituents may include charantin, and a polypeptide which has been called p-insulin (plant insulin or polypeptide-p).¹⁰ P-insulin has been compared structurally and pharmacologically to bovine insulin. In type 1 diabetics, Baldwa et al studied the effect of p-insulin on nine human diabetic patients and found its onset of action at about 30-60 minutes and a peak hypoglycemic effect after four hours.¹¹ Animal studies have had conflicting results.¹²⁻¹⁵ The hypoglycemic effects of this plant may involve increased glucose utilization by the liver;¹³ decreased glucose synthesis by depression of the two key gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-biphosphatase; and

Table 1. Nutrients and Botanicals for Managing Diabetes

COMPOUND	DOSE	ADVERSE OR OVERDOSE EFFECTS
Vanadium	0.2 mg/kg/day	Anorexia, vomiting, possible renal toxicity ²²
Vanadyl sulfate	1 mg/kg/day	Anorexia, vomiting, possible renal toxicity ²²
Chromium	50-400 mcg/day	anorexia, vomiting, possible renal toxicity ²²
Fish oil	100 mg of combined EPA/DHA per kg of body weight, divided daily	Nausea, possible platelet effects that have not proven clinically significant
alpha-Lipoic Acid	Cats: no more than 25 mg/day. Dogs: up to 200 mg/day for large dogs	Anorexia, disorientation, seizures at high doses
Vitamin C	50 mg/kg, up to 3000 mg daily in large dogs	Diarrhea at large doses
Gymnema	100-400 mg of extract divided daily or 250-1500 mg dried herb divided daily	None reported
Fenugreek	Published doses vary widely; 20-100 gm of seed powder daily in divided doses with meals in human studies (adjust dose by weight of animal)	Probably safe; may cause GI distress in high doses
Panax ginseng	50-1000 mg three times daily	Long term use at high doses may lead to agitation, hypertension, diarrhea, but appears rare
Panax quinquefolius	50-1000 mg three times daily	No reports of adverse effects but may be similar to those of P. ginseng

enhancement of glucose oxidation through the shunt pathway via activation of glucose-6-phosphate dehydrogenase.¹⁴

The defatted seeds of *Trigonella foenum-graecum* (fenugreek) have been shown

to lower blood glucose in both humans and dogs.¹⁶ Fenugreek seeds contain fiber thought to slow glucose absorption from the gut. Since aqueous extracts have also shown hypoglycemic activity in rats, this herb may work by a

number of mechanisms. In a study of rats given alloxan to induce diabetes, both water and alcohol extracts of fenugreek had some hypoglycemic activity.¹⁷ Since alloxan destroys pancreatic beta-cells, it was presumed that fenugreek either stimulated insulin release from remaining beta-cells or had insulin-receptor activity.

Two species of ginseng have shown promise in managing diabetes. *Panax ginseng* (Chinese or Korean ginseng) and *Panax quinquefolius* (American ginseng) have been shown to reduce hyperglycemia in type 2 human patients.^{18,19} The mechanism of action by which ginseng works is unknown, but effects on insulin secretion and receptor sensitivity have been suggested.¹⁸

Although herbal medicine offers potential in the treatment of diabetes in dogs and cats, few studies on efficacy and safety have been published. They still, however, may be useful in regulating difficult diabetic patients. Doses for some of these herbs are given in Table 1.

Glandulars

Glandular therapy is another alternative occasionally recommended. A glandular is an extract of a specific organ or gland, given to support the functioning of that organ. For example, pancreatic glandulars contain freeze-dried pancreatic tissue, as well as small amounts of pancreatic enzymes.

Recent research in immune tolerance has led to the investigation of oral tolerization in the treatment of autoimmune disease, including diabetes in humans.²⁰ The specific mechanism of action is unknown, but may involve deletion, anergy, or active suppression of T-lymphocytes that initiate immune destruction of target tissues. Since 40-50 percent of dogs have autoantibodies to islet cell antigens, administration of pancreatic glandulars may be a rational approach in this species. Recently, questions have arisen regarding the safety of glandular therapy, as oral tolerization may

exacerbate the immune response to autoantigens instead of tolerizing T-lymphocytes.²¹ Glandular therapy is best used early in the disease to decrease destruction of pancreatic beta-cells. This author has observed few positive results using glandular therapy.

Regulators of Insulin Receptor and Post-Receptor Effects

Unpublished research from Colorado State University's School of Veterinary Medicine²² lends support to the use of vanadium in treating diabetes in cats. Vanadium appears to have insulin-like effects in both people and experimental animals. Vanadium may be of most use in type 2 diabetes, where it is thought to activate tyrosine kinase intracellularly to act as an insulin co-factor. In one study, vanadium as an adjunct to PZI insulin therapy resulted in lower insulin doses, lower serum fructosamine values, and fewer clinical signs including polyuria and polydipsia in diabetic cats.²³

Chromium is thought to increase receptor number, receptor sensitivity, and receptor phosphorylation. Recent unpublished research by the Iams Company suggests chromium is effective at improving glucose tolerance in dogs. In a study of eight dogs fed chromium tripicolinate at 300 ppb in their diet, glucose clearance from the blood increased by 10 percent compared to another eight dogs fed the same diet not supplemented with chromium.²⁴

Other studies have not found significant benefit from chromium supplementation. In a study on non-diabetic obese and non-obese cats, chromium was supplemented at 100 mcg elemental chromium daily for six weeks. Intravenous glucose tolerance tests were administered prior to supplementation and at the end of the test period. Chromium supplementation did not affect glucose tolerance in either group.²⁵ In a study of seven obese diabetic cats, six normal weight diabetic cats, and six non-

diabetic, normal weight cats, supplementation of 100 mcg chromium as picolinate did not result in clinically significant changes.²⁶

A different group examined the effects of supplementing up to 400 mcg twice daily (20-60 mcg/kg/day) to naturally occurring diabetic dogs for a period of three months. In this study, there were no differences in serum fructosamine, blood glycated hemoglobin concentration, body weight, insulin dosage, 10-hour mean blood glucose concentration, or daily caloric intake when dogs were administered chromium plus insulin versus insulin alone.²⁷

Prevention and Treatment of Complications of Diabetes

There is little doubt that diabetes imposes oxidative stress on many tissues and organs, although the effects of oxidative stress and endothelial dysfunction are much more evident in human conditions such as diabetic cataracts, peripheral vascular disease, and diabetic nephropathy. Supplementation of various antioxidants, including vitamins C and E, has support in the human medical literature.²⁸ Vitamin E improves vascular reactivity and oxidative stress indices in human diabetics,²⁹ while vitamin C reduces plasma free radicals as well as insulin levels in human type 2 diabetic patients.³⁰

Alpha-lipoic acid has been shown to improve neuropathic deficits of diabetes in humans,³¹ but efficacy in feline diabetic neuropathy has been questionable in practice. Alpha-lipoic acid has also been used to slow the progression of cataracts in humans. Caution should be advised with this nutrient, however, as unpublished research from the University of California at Davis has shown that cats may demonstrate signs of neurologic toxicity when doses exceed 25 mg per day.³²

Oxidative stress likely affects many tissues and functions, including insulin resistance and beta-cell destruction.³³ The role of

antioxidants has not been examined in diabetic dogs and cats, but it is reasonable to postulate that antioxidants may be helpful and should be strongly considered. Veterinary antioxidant supplements are readily available and appear safe for long-term use.

Marine fish oil, a source of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA), has been suggested to increase insulin sensitivity, preventing insulin resistance.³⁴ It has been suggested as a treatment for diabetic neuropathy as well.^{35,36} Possible mechanisms of action by which fish oil exerts these effects may be via changes in cell membrane composition or transmembrane ion transport.^{37,38} Because cats are more prone to type 2 diabetes and diabetic neuropathy than dogs, fish oil seems especially appropriate as a supplement for feline diabetes mellitus.

Practical Use of Supplements

While only anecdotal experience is available as a guide on proper use of these and other adjunctive diabetes treatments, most of these supplements are quite safe, even in combination. In the author's experience, vanadium, fish oil, and antioxidants are relatively safe and appear effective for most diabetic patients. While it is unclear how much time should elapse before changing or instituting new treatment, some interventions such as vanadium have appeared to alter insulin requirements quickly – within a matter of days to weeks. On the other hand, the time required to improve longstanding tissue changes secondary to chronic hyperglycemia might be expected to take weeks to months. This author usually assesses response to therapy one to two months after instituting a new supplement.

For those pet owners willing to give a larger number of oral medications, other nutrients, herbs, and Chinese herbal combinations may be helpful. Knowledge of mechanisms of action, when available, will be helpful in guiding small animal veterinarians, since

dogs and cats often experience (in general) different forms of the disease. Except in occasional cases, it is important to keep in mind these supplements are experimental and cannot be relied on to maintain control of diabetes in the absence of insulin therapy.

Conclusion

The nutrients and botanicals described above may aid in regulation of glucose levels in difficult cases of diabetes. Other supplements are being investigated, including niacin, arginine, magnesium, and other herbs. They have the potential to reduce insulin requirements and provide more even glycemic control. The case can be made for using most of these supplements early in the disease, in hopes of slowing beta-cell destruction and amyloid deposition.

References

1. Chastain CB, Panciera D, Waters C. Effect of dietary insoluble fiber on control of glycemia in cats with naturally acquired diabetes mellitus *Sm Anim Clin Endocrinol* 2000;10:17.
2. Nelson RW, Duesberg CA, Ford SL, et al. Effect of dietary insoluble fiber on control of glycemia in dogs with naturally acquired diabetes mellitus. *J Am Vet Med Assoc* 1998;212:380-386.
3. Kimmel SE, Michel KE, Hess RS, Ward CR. Effects of insoluble and soluble dietary fiber on glycemic control in dogs with naturally occurring insulin-dependent diabetes mellitus. *J Am Vet Med Assoc* 2000;216:1076-1081.
4. Diez M, Hornick JL, Baldwin P, et al. The influence of sugar-beet fibre, guar gum and inulin on nutrient digestibility, water consumption and plasma metabolites in healthy Beagle dogs. *Res Vet Sci* 1998;64:91-96.
5. Diez M, Hornick JL, Baldwin P, Istasse L. Influence of a blend of fructo-oligosaccharides and sugar beet fiber on nutrient digestibility and plasma metabolite concentrations in healthy beagles. *Am J Vet Res* 1997;58:1238-1242.
6. Miller JC, Colagiuri S. The carnivore connection: dietary carbohydrate in the evolution of NIDDM. *Diabetologia* 1994;37:1280-1286.
7. Persaud SJ, Al-Majed H, Raman A, Jones PM. *Gymnema sylvestri* stimulates insulin release in vitro by increased membrane permeability. *J Endocrinol* 1999;163:207-212.
8. Shanmugasundaram ER, Gopinath KL, Radha Shanmugasundaram KR, Rajendran VM. Possible regeneration of the islets of Langerhans in streptozotocin-diabetic rats given *Gymnema sylvestri* leaf extracts. *J Ethnopharmacol* 1990;30:265-279.
9. Shanmugasundaram KR, Panneerselvam C, Samudram P, Shanmugasundaram ER. Enzyme changes and glucose utilisation in diabetic rabbits: the effect of *Gymnema sylvestri*, R.Br. *J Ethnopharmacol* 1983;7:205-234.
10. Cunnick J, Takemoto D. Bitter melon (*Momordica charantia*). *J Nat Med* 1993;4:16-21.
11. Baldwa VS, Bhandari CM, Pangaria A, Goyal RK. Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant sources. *Ups J Med Sci* 1977;82:39-41.
12. Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. *J Nat Prod* 1981;44:648-655.
13. Sarkar S, Pravana M, Marita R. Demonstration of the hypoglycemic action of *Momordica charantia* in a validated animal model of diabetes. *Pharmacol Res* 1996;33:1-4.
14. Shibib BA, Khan LA, Rahman R. Hypoglycemic activity of *Coccinia indica* and *Momordica charantia* in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. *Biochem J* 1993;292:267-270.
15. Day C, Cartwright T, Provost J, Bailey CJ. Hypoglycaemic effect of *Momordica charantia* extracts. *Planta Med* 1990;56:426-429.
16. Ribes G, Sauvaire Y, Da Costa C, et al. Antidiabetic effects of subfractions from fenugreek seeds in diabetic dogs. *Proc Soc Exp Biol Med* 1986;182:159-166.
17. Abdel-Barry JA, Abdel-Hassan IA, Al-Hakim MH. Hypoglycaemic and antihyperglycaemic effects of *Trigonella foenum-graecum* leaf in normal and alloxan induced diabetic rats. *J Ethnopharmacol* 1997;58:149-155.

18. Vuksan V, Stavro MP, Sievenpiper JL, et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. *Diabetes Care* 2000;23:1221-1226.
19. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. *Diabetes Care* 1995;18:1373-1375.
20. Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. *Crit Rev Immunol* 2000;20:1-16.
21. Hanninen A. Prevention of autoimmune type 1 diabetes via mucosal tolerance: is mucosal autoantigen administration as safe and effective as it should be? *Scand J Immunol* 2000;52:217-225.
22. Greco DS. Treatment of non-insulin-dependent diabetes mellitus in cats using oral hypoglycemic agents. In: Bonajura JD, ed. *Current Veterinary Therapy XIII*. Philadelphia, PA: W.B. Saunders; 1999:350.
23. Greco DS. Treatment of feline diabetes mellitus (dm) with pzi and transition metals. *American Association of Feline Practitioners Fall Meeting*. Nashville, TN; October 16-19, 1999.
24. Reinhart GA, Carey DP. *Recent Advances in Canine and Feline Nutrition, Volume II*. Wilmington, OH: Orange Frazer Press; 1998.
25. Cohn LA, Dodam JR, McCaw DL, Tate DJ. Effects of chromium supplementation on glucose tolerance in obese and nonobese cats. *Am J Vet Res* 1999;60:1360-1363.
26. Chastain CB, Panciera D, Waters C. Effects of chromium supplementation on glucose tolerance in obese and nonobese cats. *Sm Anim Clin Endocrinol* 2000;10:11.
27. Schachter S, Nelson RW, Kirk CA. Oral chromium picolinate and control of glycemia in insulin-treated diabetic dogs. *J Vet Intern Med* 2001;15:379-384.
28. Cunningham JJ. Micronutrients as nutraceutical interventions in diabetes mellitus. *J Am Coll Nutr* 1998;17:7-10.
29. Paolisso G, Tagliamonte MR, Barbieri M, et al. Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients. *J Clin Endocrinol Metab* 2000;85:109-115.
30. Paolisso G, Balbi V, Volpe C, et al. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. *J Am Coll Nutr* 1995;14:387-392.
31. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. *Diabetes Care* 1999;22:1296-1301.
32. Hill A. Personal communication. School of Veterinary Medicine, University of California, Davis.
33. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. *Diabetes Metab* 2000;26:163-176.
34. Mori Y, Murakawa Y, Yokoyama J, et al. Effect of highly purified eicosapentaenoic acid ethyl ester on insulin resistance and hypertension in Dahl salt-sensitive rats. *Metabolism* 1999;48:1089-1095.
35. Podolin DA, Gayles EC, Wei Y, et al. Menhaden oil prevents but does not reverse sucrose-induced insulin resistance in rats. *Am J Physiol* 1998;274:R840-R848.
36. Okuda Y, Mizutani M, Ogawa M, et al. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. *J Diabetes Complications* 1996;10:280-287.
37. Gerbi A, Maixent JM, Ansaldi JL, et al. Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats. *J Nutr* 1999;129:207-213.
38. Stiefel P, Ruiz-Gutierrez V, Gajon E, et al. Sodium transport kinetics, cell membrane lipid composition, neural conduction and metabolic control in type 1 diabetic patients. Changes after a low-dose n-3 fatty acid dietary intervention. *Ann Nutr Metab* 1999;43:113-120.